Clinical Experience with Daptomycin in Pediatrics

Pharmacotherapy

Volumn 37, Issue 1, 2017, Pages 105-108

  Namtu, Katie C ^a   Crain, Julianna C ^a   Messina, Allison F ^a   Dumois, Juan A ^a   Berman, David M ^a  

^a JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

Author keywords

antibiotics; antimicrobials; daptomycin; gram positive infections; pediatrics

Indexed keywords

CREATINE KINASE; DAPTOMYCIN; LINEZOLID; ANTIINFECTIVE AGENT;

ABSCESS; ADOLESCENT; ADULT; ARTICLE; BACTEREMIA; BACTERIAL ARTHRITIS; BONE INFECTION; CATHETER INFECTION; CATHETER REMOVAL; CHILD; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAM POSITIVE INFECTION; HIP ABSCESS; HIP DISEASE; HOSPITALIZED CHILD; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MIXED INFECTION; OSTEOMYELITIS; PERITONITIS; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; WOUND INFECTION; BLOOD; CATHETER-RELATED INFECTIONS; PRESCHOOL CHILD;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CATHETER-RELATED INFECTIONS; CHILD; CHILD, PRESCHOOL; CREATINE KINASE; DAPTOMYCIN; FEMALE; HUMANS; INFANT; MALE; RETROSPECTIVE STUDIES;

EID: 85008462061     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1872     Document Type: Article

References (14)

1. Cubist Pharmaceuticals US. Cubicin package insert. Lexington, MA; 2014. Available from http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin.cfm
2. Abdel-Rahman SM, Benziger DP, Jacobs RF, Jafri H, Hong EF, Kearns GL. Single-dose pharmacokinetics of daptomycin in children with suspected or proved Gram-positive infections. Pediatr Infect Dis J 2008;27(4):330–4.
3. Abdel-Rahman SM, Chandorkar G, Akins RL, et al. Single-dose pharmacokinetics and tolerability of daptomycin 8 to 10 mg/kg in children aged 2 to 6 years with suspected or proved gram-positive infections. Pediatr Infect Dis J 2011;30(8):712–4.
4. Antachopoulos C, Iosifidis E, Sarafidis K, et al. Serum levels of daptomycin in pediatric patients. Infection 2012;40:367–71.
5. Ardura MI, Mejias A, Katz KS, Revell P, McCracken GH, Sanchez PJ. Daptomycin therapy for invasive gram-positive bacterial infections in children. Pediatr Infect Dis J 2007;26:1128–32.
6. Bradley JS, Benzinger D, Bokesch P, Jacobs R. Single-dose pharmacokinetics of daptomycin in pediatric patients 3–24 months of age. Pediatr Infect Dis J 2014;33(9):936–9.
7. Cohen-Wolkowiez M, Watt KM, Hornick CP, Benjamin DK, Smith PB. Pharmacokinetics and tolerability of single-dose daptomycin in young infants. Pediatr Infect Dis J 2012;31(9):935–7.
8. Larru B, Cowden CL, Zaoutis TE, Gerber JS. Daptomycin use in United States children's hospitals. J Pediatr Infect Dis Soc 2014;4(1):60–2.
9. Meije Y, Almirante B, Del Pozo JL, et al. Daptomycin is effective as antibiotic-lock therapy in a model of Staphylococcus aureus catheter-related infection. J Infect 2014;69:548–52.
10. Burgess LD, Drew RH. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy 2014;34(7):670–6.
11. Moenster RP, Linneman TW, Finnegan PM, et al. Acute renal failure associated with vancomycin and β-lactams for the treatment of osteomyelitis in diabetics: piperacillin-tazobactam as compared with cefepime. Clin Microbiol Infect 2014;20:O384–9.
12. Hawkey PM. Pre-clinical experience with daptomycin. J Antimicrob Chemother 2008;62(3):iii7–14.
13. French GL. Bactericidal agents in the treatment of MRSA infections: the potential role of daptomycin. J Antimicrob Chemother 2006;58:1107–17.
14. Kullar R, Chin JN, Edwards DJ, Parker D, Coplin WM, Rybak MJ. Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections. Antimicrob Agents Chemother 2011;55(7):3505–9.